ClinicalTrials.gg
WithdrawnNCT01616719Updated Mar 4, 2020

Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease

An interventional study of DTRAX Graft in Cervical Spondylosis, Cervical Radiculopathy and Cervical Degenerative Disc Disease, sponsored by Providence Medical Technology, Inc.. Withdrawn at 2 sites in United States. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Providence Medical Technology, Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
study was never started due to lack of resources

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Spondylosis with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Spondylosis · United States.

Enrollment
42nd of 45
0 · median 45
Started
2012
with 2 others
No phase
34 of 63
8 open now
Registered
8th of 63
by date

Among the 63 studies in Spondylosis with a site in United States, this one is the 42nd largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2012, is one of 34 with no phase, and was the 8th registered.

Spondylosis

142 studies on the registry are indexed under Spondylosis; 41 are open to participants now.

Browse Spondylosis studies →

Open to participants now

17 of the 63 studies in Spondylosis with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Spondylosis studies recruiting now, 12 (44%) set no upper age limit and 10 (37%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Spondylosis with a site in United States, or all of them as a file.
02

Study summary

DTRAX Graft is used to relieve nerve pressure in the neck in order to provide relief for Cervical Degenerative Disc Disease. This study is being conducted to determine the effectiveness of the graft, and to find out whether or not it provides better results or faster healing than traditional ways of performing surgery for Cervical Degenerative Disc Disease.

03

Conditions studied

  • Cervical Spondylosis
  • Cervical Radiculopathy
  • Cervical Degenerative Disc Disease
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject diagnosed with DDD in C3-C7, defined as follows:

    • Radiographically (at least one):

      • degenerated disc on MRI;
      • decreased disc height on plain film, CT or MRI; and/or
      • disc herniation, as demonstrated by CT or MRI.
    • Clinically: radicular symptoms (at least one):

      • arm/shoulder pain;
      • decreased reflexes;
      • decreased strength; and/or
      • decreased sensation.
  2. Subject has single-level disease, OR multi-level disease demonstrated radiographically, and confirmed to be symptomatic by one of the following methods:

    • Selective nerve root block, OR
    • EMG, OR
    • Distinctive clinical examination.
  3. Subject has dynamic stenosis relieved by traction and made worse by a Spurlings maneuver.
  4. Subject is 35-80 years of age, inclusive.
  5. Subject is unresponsive to 6 weeks conservative, nonoperative treatment, or has the presence of progressive symptoms or signs of nerve root compression in face of combined nonoperative management.
  6. Preoperative NDI score of ≥ 30.
  7. Preoperative neck pain and arm pain score of ≥ 6 on Neck and Arm Pain Scales.
  8. Patient is a male or non-pregnant, non-lactating female.
  9. Female patients of , including those who have had a tubal ligation, but excluding those who have not experienced a menstrual period for at least two years, must have a negative urine pregnancy test at Screening.
  10. Patient must voluntarily provide written, .
  11. Subject is able to meet the proposed follow-up schedule.
  12. Subject is able to follow the postoperative management program.

Exclusion criteria

Exclusion Criteria:

  1. Subject has severe osteopenia, osteoporosis, osteomalacia, spinal , or metabolic bone disease OR the level of BMD is a T score of -2.5 or below OR patient has sustained a vertebral compression or nontraumatic hip or wrist fracture.
  2. Subject has overt or active spinal and/or systemic infection.
  3. Subject has spondylolisthesis ≥ 3.5mm or rotator subluxation.
  4. Subject has cervical myelopathy.
  5. Subject has a chronic pain syndrome.
  6. Subject has radicular findings with major motor impairment.
  7. Subject has a condition that requires postoperative medications that interfere with fusion or the stability of the implant, such as .
  8. Subject is mentally incompetent.
  9. Subject is a prisoner.
  10. Subject is pregnant.
  11. Subject abuses alcohol or drugs.
  12. Subject has a cervical spinal condition other than symptomatic cervical disc disease requiring surgical treatment at the involved level.
  13. Subject has insulin dependent diabetes.
  14. Subject has chronic or acute renal failure or prior history of renal disease.
  15. Subject has fever at the time of surgery, defined as > 38.5 degrees C.
  16. Subject has documented allergy or intolerance to stainless steel, titanium, or a titanium alloy.
  17. Subject has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of DTRAX surgery.
  18. Subject has history of an endocrine or metabolic disorder known to affect osteogenesis .
  19. Subject has had treatment with an therapy within 28 days prior to DTRAX surgery or such treatment is planned during the 16 weeks following implantation of DTRAX Graft.
  20. Subject is involved in spinal litigation or Workmen's Compensation claim.
  21. Subject is obese, defined as (BMI) > 35.
  22. Patient has psychiatric history, head injury or any other condition, which, in the Investigator's opinion, would prevent the patient from complying with postoperative follow-up visits.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    DTRAX graft

    Device: DTRAX Graft

Interventions

  • DeviceDTRAX Graft

    DTRAX Graft is an allograft implant inserted to support spinal fusion.

06

What researchers measure

Primary outcomes

  1. Gather clinical outcome data on DTRAX Graft.

    Clinical outcome data will be collected using the Neck Disability Index (NDI), Visual Analogue Scale (VAS), and a quality of life questionnaire.

    Time frame: Baseline throughout 12 months post-operatively

Secondary outcomes

  1. Safety information will be evaluated by collecting the type, frequency, severity, device, and procedure-relatedness of adverse events.

    Time frame: Baseline throughout 12 months post-operatively

07

Study locations

2 sites
  • Office of Dr. Brian Andrews, Neurosurgery
    San Francisco, California 94114, United States
  • Neurospine Institute Medical Group
    San Francisco, California 94115, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2012; primary completion for Feb 2014, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2012
First posted
Jun 12, 2012
StartEst.
May 2012
Primary completionEst.
Feb 2014
CompletionEst.
Feb 2015
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01616719
Lead sponsor
Providence Medical Technology, Inc.
Responsible party
Sponsor
First posted
Jun 12, 2012
Start date
May 2012 (estimated)
Primary completion
Feb 2014 (estimated)
Completion
Feb 2015 (estimated)
Last update
Mar 4, 2020

Study contacts

Bruce McCormack, M.D.
principal investigator · Neurospine Institute Medical Group
Brian Andrews, M.D.
principal investigator · Office of Dr. Brian Andrews, Neurosurgery
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion